Judge Glenda Hatchett to Receive ElevateMeD Trailblazer Award at Ignite Atlanta
Renowned Judge, Advocate, and TV Personality Honored for Her Commitment to Justice and Equity in Healthcare
'I am grateful to receive this award and very much appreciate the essential, transformational, empowering systemic advocacy of ElevateMeD as it works to address the alarming disparities in healthcare.' — Judge Glenda Hatchett
ATLANTA, GA, UNITED STATES, March 25, 2025 / EINPresswire.com / -- ElevateMeD is honored to announce that the esteemed Judge Glenda Hatchett will be presented with the ElevateMeD Trailblazer Award at its upcoming Ignite Atlanta event on Friday, April 25, 2025, at The Piedmont Room. Judge Hatchett's illustrious career spans groundbreaking roles in law, corporate leadership, and television, reflecting her unwavering commitment to justice and healthcare advocacy.
'I am grateful to receive this award and very much appreciate the essential, transformational, empowering systemic advocacy of ElevateMeD as it works to address the alarming disparities in the healthcare system in this country,' said Judge Hatchett. 'We should all support the work of ElevateMeD as they are working to change the medical landscape today and for generations to come.'
A native of Atlanta, Judge Hatchett earned her B.A. in political science from Mount Holyoke College in 1973 and her J.D. from Emory University School of Law in 1977. She began her legal career with a prestigious federal clerkship in the United States District Court for the Northern District of Georgia. Judge Hatchett then joined Delta Air Lines, where she became the company's highest-ranking woman of color worldwide, serving as both senior attorney and public relations manager. In 1990, she made history as Georgia's first African American Chief Presiding Judge of a state court when she was appointed to the Fulton County Juvenile Court. Beyond the bench, Judge Hatchett is widely recognized for her nationally syndicated television show, 'Judge Hatchett,' and her current program, 'The Verdict with Judge Hatchett.' She is also the founder of The Hatchett Firm, P.C., based in Atlanta, specializing in catastrophic injuries and police misconduct cases.
Judge Hatchett's dedication to empowering underserved communities aligns seamlessly with ElevateMeD's mission to cultivate the next generation of diverse physician leaders. Her multifaceted career and passion for justice make her a trailblazer in every sense.
The Ignite Atlanta event celebrates six years of ElevateMeD's impact in diversifying the physician workforce to address health disparities. With over $1.2 million invested in underrepresented medical students, ElevateMeD's Scholars Program offers comprehensive support, including scholarships, mentorship, leadership development, and financial literacy training.
As this milestone event continues to gain momentum, ElevateMeD is proud to recognize Truist Bank as the Ignite Atlanta White Coat Sponsor. With a substantial donation, Truist has demonstrated its deep commitment to advancing health equity and supporting the next generation of diverse medical leaders through their alignment with the financial literacy pillar of the ElevateMeD programming. Their partnership and support of the Ignite Atlanta event further reinforce the organization's mission to transform the face of medicine through intentional investment in underrepresented communities.
The evening will also feature keynote remarks from Jahlecia Gregory, a fourth-year medical student at Morehouse School of Medicine, who is pursuing a career in psychiatry to address mental healthcare disparities among children and adolescents of color. Additional speakers include Xavier Walker, Dr. Maia McCuiston, Dr. Jeshenna Watkins, and ElevateMeD Founder Dr. Alyx Porter Umphrey, a neuro-oncologist and advocate for physician diversity.
Reflecting on the organization's journey, Dr. Porter Umphrey stated, 'When we founded ElevateMeD in 2019, we envisioned a physician workforce that mirrors the communities it serves. Six years later, our scholars are beginning their medical careers, poised to effect change and improve healthcare outcomes for all.'
Ignite Atlanta serves as both a celebration of ElevateMeD's achievements and a fundraiser to support future scholars. Supporters, alumni, and community members are invited to join this special event. For more information, to donate, or to learn more about ElevateMeD's initiatives, please visit ignite.elevatemed.org.
About ElevateMeD
ElevateMeD is a 501(c)(3) nonprofit organization committed to elevating medicine by providing scholarships, mentorship, leadership training, and financial literacy education to future physicians from African-American/Black, Hispanic/Latino, and Native/Indigenous backgrounds. Through our Scholars Program, we aim to increase physician workforce diversity and improve cultural competence among physicians to reduce health disparities. Learn more about our mission and vision by visiting elevatemed.org and following us on Instagram, Twitter, and Facebook @elevatemedinc.
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 days ago
- Medscape
Small Ear-Wax Sample, Big Diagnostic Clues
A recent BBC report suggests that cerumen, commonly known as earwax, may harbor biomarkers to aid in the diagnosis and monitoring of conditions such as cancer, Alzheimer's disease, and metabolic disorders. Cerumen Profile The primary function of cerumen is to keep the external auditory canal clean and lubricated, preventing invasion by bacteria, fungi, and insects. Beyond this, cerumen may reflect systemic metabolism by concentrating a broader array of compounds than blood, urine, sweat, and tears. Its relative stability allows the accumulated cerumen to provide long-term snapshots of metabolic changes. Disease Associations Researchers have defined genetically determined wet and dry cerumen phenotypes. In the US, Caucasian, African American, and German women with wet cerumen faced roughly four times the risk of dying from breast cancer compared with Japanese and Taiwanese women with dry cerumen. The study found that Japanese women with breast cancer were more likely to carry the wet-cerumen allele than were healthy controls. However, large-scale studies in Germany, Australia, and Italy failed to confirm these associations. A recent analysis reported that patients with Ménière's disease had lower levels of three fatty acids in the cerumen compared with healthy controls — the first biomarker identified for that disorder. In a 2019 study led by Nelson Roberto Antoniosi Filho, PhD (Federal University of Goiás Goiânia in Brazil), researchers analyzed cerumen samples from 52 patients with lymphoma, carcinoma, or leukemia and 50 healthy volunteers, using a method that identifies volatile organic compounds (VOCs). The researchers identified 27 VOCs that served as diagnostic fingerprints for cancer, predicting the cancer status with 100% accuracy. The assay could not distinguish among cancer types, indicating that these VOCs represent a general response to malignant cells. Another investigation by the same group showed that cerumen analysis can detect metabolic disturbances in premalignant stages when cells exhibit dysplastic changes that may lead to cancer but remain nonmalignant, potentially enabling much earlier intervention. The team is also investigating whether metabolic alterations caused by neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, can be detected in the cerumen. Diagnostic Tool Antoniosi Filho and colleagues proposed that cancer, as a mitochondrial metabolic disorder, releases VOCs that accumulate in cerumen, allowing differentiation between healthy and cancerous individuals via an assay they call the cerumenogram. The aim was to develop a cerumenogram as a diagnostic tool to accurately predict certain cancers from a small cerumen sample. Clinical Adoption Hospital Amaral Carvalho in Jaú, São Paulo — a national reference center for oncology and bone marrow transplantation — has recently implemented cerumenograms for cancer diagnosis and monitoring. Future Directions An April 2025 paper in Scientific Reports by Antoniosi Filho concluded that the cerumenogram could: 1. Identify oncologic risk by detecting premalignant cells before cancer onset, introducing a novel screening modality 2. Show that mitochondrial impairment in premalignant cells — such as hypermetabolic inflammation and dysplasia — produces the same VOC biomarkers as malignant cells, distinct from those in benign lesions, opening new paths for risk management and early intervention 3. Correlate cerumenogram findings with established imaging techniques such as 2-deoxy-2-[fluorine-18] fluoro-D-glucose PET/CT (18F-FDG PET/CT) and gallium-68 PSMA PET/CT, demonstrating alignment with clinical results while offering a noninvasive, lower-cost alternative 4. Monitor treatment response and cancer remission, supporting assessment of therapeutic efficacy and cellular return to normal 5. Confirm metabolic indicators of malignancy to guide clinical decisions alongside imaging and biopsy 6. Drive the development of targeted therapies aimed at metabolites overproduced in malignant conditions. In conclusion, the cerumenogram may serve as a valuable assay for evaluating precancerous indicators, cancer progression, and remission, with the potential to reduce mortality, alleviate patient suffering, and lower disease-related costs. Congratulations to Nelson Roberto Antoniosi Filho, PhD, and his team.
Yahoo
5 days ago
- Yahoo
Race and genetics do not line up well, new study confirms
When you buy through links on our articles, Future and its syndication partners may earn a commission. The racial and ethnic groups people identify with may not accurately represent their genetic backgrounds or ancestries, a new study of people in the United States suggests. This discrepancy between people's self-reported identities and their genetics is important for scientists to acknowledge as they strive to develop medical treatments tailored to different patients, the researchers behind the study say. "This paper is very important because it clarifies at the highest resolution the relationship between genomic diversity and racial/ethnic categories in the US," said study co-author Eduardo Tarazona-Santos, a professor of human population genetics at the Federal University of Minas Gerais in Brazil. The findings are "critical to develop appropriate precision medicine solutions for all," he told Live Science in an email. Precision medicine tailors treatments to individual patients, taking their genes, environment and lifestyle factors into account. In their study, published Thursday (June 5) in The American Journal of Human Genetics, Tarazona-Santos and his colleagues analyzed the DNA of more than 230,000 people who contributed to the All of Us research database. This trove of data has been compiled through a National Institutes of Health program aimed at advancing precision medicine by recruiting people from diverse and underrepresented populations. Historically, many large-scale genetics studies have predominantly included people of European ancestry, making efforts like the All of Us project crucial for reducing medical inequity. However, the program has faced significant funding cuts in recent months, which has significantly slowed recruitment and progress. Related: What's the difference between race and ethnicity? Using a method called principal component analysis, the team identified genetic similarities and differences among the people included in the database. They also used genetic catalogs that contain DNA samples from all over the world, such as the 1000 Genomes Project, as a way to assess how people's genetic ancestry compared with the racial (white, Black or African American, Asian American) and ethnicity (Hispanic/Latino or not) categories used in the All of Us questionnaire. People who identified as being from the same racial and ethnic groups had a number of genetic differences, the team found. In fact, "most genetic variance is within race and ethnicity groups rather than between groups," the study authors wrote in the report. Rather than sorting people into "distinct clusters" divided by racial and ethnic lines, the analyses found that people within different races and ethnicities show "gradients" of genetic variation. "We found gradients of genetic variation that cut across those categories," the authors wrote. The new study's findings counter a controversial paper published in Nature in 2024 that had also analyzed genomic data provided by All of Us participants. At the time, the paper was criticized by some experts, who argued that the technique used to analyze the race and ethnicity data could be misconstrued to support the incorrect idea that humans can be neatly categorized into distinct races. The new study, which used a different data-crunching technique, found the opposite. The research also found that, even within the same ethnic and racial group, people show genetic variation across different U.S. states. This could reflect the "historical impacts of U.S. colonization, the transatlantic slave trade, and recent migrations," the authors wrote. A key example of this was seen in participants who identified as Hispanic or Latino and lived in states like California, Texas and Arizona, who were found to have a high proportion of Native American ancestry compared with Hispanic and Latino people in other parts of the U.S. This makes sense considering many of these states were historically part of Mexico, which has a large population of people with mixed Indigenous and European ancestries, the researchers argued. By contrast, of people who identified as Hispanic or Latino, those in New York were found to have the highest proportion of African ancestry, which is "consistent with recent migration from the Caribbean to New York." The authors said their findings show that the genetic backgrounds of people in the U.S. are highly complex and that "social constructs of race and ethnicity do not accurately reflect underlying genetic ancestry." In light of this, the researchers have said they "do not recommend using race and ethnicity as proxies for ancestry in genetic studies." RELATED STORIES —'Racism is a global public health crisis': Author Layal Liverpool says racist ideas still pervade medicine, and that hurts all of us —Scientific consensus shows race is a human invention, not biological reality —Racial bias is baked into algorithms doctors use to guide treatment Tesfaye Mersha, a professor of pediatrics and a human genetics researcher at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, said that he agrees that these self-reported categories should not be used in genetic studies. Instead, the categories should be confined to social studies "where we know they will have a big impact," he told Live Science in an email. That said, Mersha also warned against overinterpreting the study's takeaways about regional and state-level genetic variation. "Some states had very low participant numbers, which may skew regional estimates and limit generalizability," he noted. "Moreover, high population mobility across states blurs geographic boundaries, especially in the absence of multigenerational ancestry data," he said. In short, because people move around a lot, it's difficult to draw conclusions without having a clear sense of how long their families have been based in a given state.
Associated Press
6 days ago
- Associated Press
Bullpen Launches Emerging Fund to Champion the Next Generation of Life Sciences Innovators
New investment initiative fuels high-potential startups across biotools, medtech, digital health, and therapeutics. 'BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships.'— Christiaan Engstrom, CEO of Bullpen. BOSTON, MA, UNITED STATES, June 4, 2025 / / -- Bullpen, a trusted community of life sciences dealmakers, today announced the launch of its Bullpen Emerging Fund, a bold initiative designed to back mission-driven startups that are redefining the future of health. Through capital investment, deep mentorship, and access to a close-knit network of expert operators and investors, the fund aims to turn today's early-stage breakthroughs into tomorrow's clinical realities. The Emerging Fund, available to accredited investors, invests in standout companies selected for Bullpen's On-Deck class—founders chosen not only for their science but for their grit, vision, and purpose. The 2025 cohort includes: - Chandima Bandaranayaka, CEO: Precision Quantomics, accelerating drug discovery and personalized pharmacotherapy through high-resolution molecular profiling. - David Mead, CEO: Terra Bioforge, harnessing synthetic biology to streamline biological production and accelerate therapeutic development. - Doug Cohen, CEO: IR Medtek, developing real-time, noninvasive cancer detection technologies that improve early diagnosis and patient outcomes. - Harsha Rajasimha, CEO: Jeeva Clinical Trials, delivering decentralized trial software that enhances patient access, retention, and diversity in clinical research. - Linda Tempelman, CEO: Persista Bio, advancing cell therapy solutions for chronic diseases, including a novel approach to treating Type 1 diabetes. Each of these founders will pitch during Bullpen's 'Money Ball' sessions, June 16–18 at BIO International, to an audience of mission-aligned investors and partners. More than a moment on stage, these pitches represent the culmination of rigorous preparation and the start of a meaningful growth journey. 'Bullpen was built on a simple idea: if you bring the right people together in the right way, the outcomes take care of themselves. BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships that will move this industry forward,' said Christiaan Engstrom, CEO of Bullpen. Further information on the Bullpen Emerging Fund may be obtained from Ray Jordan, managing director, Putnam Insights LLC, and initial investor in the fund through Elmstead Partners LLC. Jordan may be reached at [email protected]. Expert Coaching to Catalyze Success Behind each founder is a seasoned mentor: - Michael Hill, Global Head of Science Innovations, MedTech Head Coach, with a legacy of scaling clinical tools from bench to bedside. - Stella Vnook, CEO of Likarda and Therapies Head Coach, a biotech operator with deep experience in moving science-backed products through commercial launch. - John Bonham-Carter, BioTools Head Coach and angel investor, guiding early-stage science into successful enterprise with strategic insight and operational depth. Throughout the week, Bullpen will host engaging programming across Boston innovation hubs like Portal Innovations, SmartLabs, and EPAM Continuum. Key agenda highlights include: Agenda Highlights Include: - Investor interviews with leaders from Novo Nordisk, Cincytech, DigitalDx, Mayo Clinic, Riverside Partners, and others, with open Q&A in the Press Room following each session. - Thematic forums exploring pivotal industry issues such as: - AI in Healthcare: Exploring how artificial intelligence is reshaping patient care and discovery. - Patient Access: Breaking down barriers to get therapies to those who need them most. - Tech Transfer: Bridging academic science and commercial application. - Rare Disease: Elevating patient voices and rare innovation journeys. - Global Forums: Perspectives from Japan, Korea, Canada, and Australia spotlighting international innovation. - Women in VC and venture insights sessions, giving voice to underrepresented perspectives in capital formation and funding trends. As BIO Week wraps, Bullpen leaves behind more than a schedule, it strengthens a movement. One that champions science, centers people, and dares to do things differently. With the Emerging Fund as its catalyst, Bullpen is helping the next generation of health innovators go further, faster. About Bullpen: Founded on the mantra Find Someone to Help. Repeat., Bullpen is a volunteer-led, member-driven network designed to foster meaningful connections and accelerate innovation in life sciences. With no booths or sales pitches, Bullpen cultivates a space where authentic conversation drives real outcomes. Its members include public and private company leaders, VCs, strategics, accelerators, and non-profit executives dedicated to building the future of health. Media Inquiries: Madelyn De Los Santos Putnam Insights email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
